^
Association details:
Biomarker:No biomarker
Cancer:Neuroendocrine Tumor
Drug:temozolomide (DNA synthesis inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Published date:
01/19/2021
Excerpt:
Recommendations: Dacarbazine/temozolomide–based ChT as first line, and platinum-based ChT as second line, are recommended in advanced LC patients refractory or intolerant to everolimus therapy [IV, C]….Upfront everolimus or dacarbazine/temozolomide–based or oxaliplatin-based ChT is recommended, or in selected subgroup PRRT (based on positive uptake at SRI on all RECIST evaluable targets) in high proliferative atypical carcinoids [V, C].
DOI:
10.1016/j.annonc.2021.01.003
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Neuroendocrine Tumors of the Gastrointestinal Tract (Well-Differentiated Grade 1/2): Locoregional Advanced Disease and/or Distant Metastases (if progression on octreotide or lanreotide)...Useful in Certain Circumstances...Cytotoxic chemotherapy, if no other options feasible (all category 3): Anticancer agents such as 5-fluorouracil (5-FU), capecitabine, dacarbazine, oxaliplatin, streptozocin, and temozolomide can be used in patients with progressive metastases for whom there are no other treatment options....Preferred regimens...Temozolomide + capecitabine (preferred when tumor response is needed for symptoms or debulking).
Secondary therapy:
capecitabine
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
TEM alone or in combination with CAP is recommended as alternative ChT in Pan-NETs…